Reports related to this article:
Project(s): View 5 related projects in PECWeb
Plant(s): View 3 related plants in PECWeb
Released March 12, 2014 | SUGAR LAND
en
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--Before 2014 draws to a close, the Pharmaceutical-Biotech Industry is forecast to open the doors of 90 new plants and research centers across North America. A recent survey of reported projects in Industrial Info's Pharmaceutical Tracker - Online Database reveals that cumulatively, the projects represent a potential total investment value (TIV) of $3.9 billion, which includes both original construction costs and possible future phases that already are planned or under consideration. The projects reported include grassroot facilities, building additions, and the repurposing of existing sites.
Click on the image at right to see a regional breakdown of 2014 plant startups sourced out of the North American Pharmaceutical & Biotech Industry.
An analytical look at the projects reveals the industry will have gained 31 more sites than the 59 that opened in 2013. The TIV potential for all of the new sites for 2014 increased 33% (or $1 billion) from last year's total of $3 billion. The 2014 site average potential TIV is $44 million, a slight dip from 2013's site average of $51 million. Sources for the new-build activity include private industry, commercial developers, universities and the federal government.
Click here to gain instant access to the all-new 2014 North American Pharmaceutical-Biotech Outlook.
The facilities that are scheduled to open their doors from January through December 2014 are as varied a group as the industry itself. If each one opens, there is a potential for 12,000 jobs, either created or retained.
In Baltimore, Maryland, the Forest City-East New Baltimore Partnership (Baltimore, Maryland) was tapped to develop a five-story, 225,000-square-foot building to house Maryland's public health lab. Designed by HDR CUH2a (Bethesda, Maryland) and built by Turner Construction (Baltimore), the $219 million project should open later this year, and will perform research and response into public health threats. Housing 41 biosafety laboratories, the building will be able to conduct research all the way up to Biosafety Level 3 (BSL-3). According to the Centers for Disease Control and Prevention (CDC), "Biosafety Level 3 is applicable to clinical, diagnostic, teaching, research, or production facilities where work is performed with indigenous or exotic agents that may cause serious or potentially lethal disease through the inhalation route of exposure." This type of research is vital when considering public health.
Ipsen Biomeasure (Milford, Massachusetts) is investing $35 million to build out almost 63,000 square feet of space in Cambridge, Massachusetts. Located within BioMed Realty Trust's (NYSE:BMR) (Cambridge, Massachusetts) 280,000-square-foot 650 East Kendall Square development, the new site will house peptide and protein-based therapeutics development, as well as the company's headquarters. Consigli Construction (Milford) is the project's general contractor.
One of the year's largest is Vertex Pharmaceuticals' (NASDAQ:VRTX) new operation in Boston, Massachusetts. Representing a potential $800 million investment, the company is taking 1.1 million square feet in the Fallon Company's Fan Pier development.
The Vertex project team includes architects Elkus Manfredi (Cambridge) and Tsoi/Kobus (Boston), who designed the two 18-story LEED certified buildings that will house all of Vertex's administrative and research operations. Vertex's lead drug pipeline candidate is a cystic fibrosis treatment in Phase III development, as well as treatments for Hepatitis C, Autoimmune Diseases and Influenza. Turner Construction (Boston) served as the project's general contractor.
A bit further south, Nephron Pharmaceuticals is investing $165 million in Cayce, South Carolina, for a grassroot manufacturing plant, training center and packaging facility. ACI Architects (Winter Park, Florida) designed the new campus, which will feature a 235,000-square-foot manufacturing plant, a 27,000-square-foot training facility, a 21,000-square-foot high-bay warehouse, and a 40,000-square-foot packaging building. Jack Jennings & Sons (Orlando, Florida) is the project construction manager. The Nephron plans call for an eventual build-out of 600,000 square feet for the site, producing the company's respiratory products.
From a regional standpoint, New England and the Northeast topped the list for the most new facilities expected in 2014. Both regions will open the doors on 14 new sites this year, with the potential of 4,600 jobs either created or maintained. The remaining plants and research laboratories are scattered across North America.
View Plant Profile - 303955 1079453 1069204 3103217
View Project Report - 300044818 300044801 35001022 26001022 300137189
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, three offices in North America and nine international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities.
Click on the image at right to see a regional breakdown of 2014 plant startups sourced out of the North American Pharmaceutical & Biotech Industry.An analytical look at the projects reveals the industry will have gained 31 more sites than the 59 that opened in 2013. The TIV potential for all of the new sites for 2014 increased 33% (or $1 billion) from last year's total of $3 billion. The 2014 site average potential TIV is $44 million, a slight dip from 2013's site average of $51 million. Sources for the new-build activity include private industry, commercial developers, universities and the federal government.
Click here to gain instant access to the all-new 2014 North American Pharmaceutical-Biotech Outlook.
The facilities that are scheduled to open their doors from January through December 2014 are as varied a group as the industry itself. If each one opens, there is a potential for 12,000 jobs, either created or retained.
In Baltimore, Maryland, the Forest City-East New Baltimore Partnership (Baltimore, Maryland) was tapped to develop a five-story, 225,000-square-foot building to house Maryland's public health lab. Designed by HDR CUH2a (Bethesda, Maryland) and built by Turner Construction (Baltimore), the $219 million project should open later this year, and will perform research and response into public health threats. Housing 41 biosafety laboratories, the building will be able to conduct research all the way up to Biosafety Level 3 (BSL-3). According to the Centers for Disease Control and Prevention (CDC), "Biosafety Level 3 is applicable to clinical, diagnostic, teaching, research, or production facilities where work is performed with indigenous or exotic agents that may cause serious or potentially lethal disease through the inhalation route of exposure." This type of research is vital when considering public health.
Ipsen Biomeasure (Milford, Massachusetts) is investing $35 million to build out almost 63,000 square feet of space in Cambridge, Massachusetts. Located within BioMed Realty Trust's (NYSE:BMR) (Cambridge, Massachusetts) 280,000-square-foot 650 East Kendall Square development, the new site will house peptide and protein-based therapeutics development, as well as the company's headquarters. Consigli Construction (Milford) is the project's general contractor.
One of the year's largest is Vertex Pharmaceuticals' (NASDAQ:VRTX) new operation in Boston, Massachusetts. Representing a potential $800 million investment, the company is taking 1.1 million square feet in the Fallon Company's Fan Pier development.
The Vertex project team includes architects Elkus Manfredi (Cambridge) and Tsoi/Kobus (Boston), who designed the two 18-story LEED certified buildings that will house all of Vertex's administrative and research operations. Vertex's lead drug pipeline candidate is a cystic fibrosis treatment in Phase III development, as well as treatments for Hepatitis C, Autoimmune Diseases and Influenza. Turner Construction (Boston) served as the project's general contractor.
A bit further south, Nephron Pharmaceuticals is investing $165 million in Cayce, South Carolina, for a grassroot manufacturing plant, training center and packaging facility. ACI Architects (Winter Park, Florida) designed the new campus, which will feature a 235,000-square-foot manufacturing plant, a 27,000-square-foot training facility, a 21,000-square-foot high-bay warehouse, and a 40,000-square-foot packaging building. Jack Jennings & Sons (Orlando, Florida) is the project construction manager. The Nephron plans call for an eventual build-out of 600,000 square feet for the site, producing the company's respiratory products.
From a regional standpoint, New England and the Northeast topped the list for the most new facilities expected in 2014. Both regions will open the doors on 14 new sites this year, with the potential of 4,600 jobs either created or maintained. The remaining plants and research laboratories are scattered across North America.
View Plant Profile - 303955 1079453 1069204 3103217
View Project Report - 300044818 300044801 35001022 26001022 300137189
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, three offices in North America and nine international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities.
